WVE 004
Alternative Names: C9orf72; WVE-004Latest Information Update: 28 Mar 2024
At a glance
- Originator WaVe life Sciences
- Class Antidementias; Antisense oligonucleotides; Neuroprotectants
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 31 Jul 2023 Wave Life Sciences terminates its collaboration with Takeda with respect to C9 Target and ATXN3 Target
- 23 May 2023 Discontinued - Phase-I/II for Amyotrophic lateral sclerosis in Australia, Canada, Ireland, United Kingdom, Belgium, Sweden, New Zealand, Netherlands (Intrathecal)
- 23 May 2023 Discontinued - Phase-I/II for Frontotemporal dementia in Netherlands, New Zealand, Sweden, Belgium, United Kingdom, Ireland, Canada, Australia (Intrathecal)